World’s first celiac vaccine gains FDA fast-track designation during Phase 2 trial

636821266076419116gluten free bakery.jpg

03 Jan 2019 --- The world's first vaccine for people who have celiac disease, Nexvax2 from ImmusanT, Inc, has secured fast-track designation from the US Food and Drug Administration (FDA). The global Phase 2 study assessing Nexvax2 is currently recruiting patients, after rolling out late in 2018. Completion of the trial is expected in the second half of 2019.

The FDA grants fast-track status to certain investigational drugs to expedite the development and review process for therapeutic candidates with the potential to fulfill the unmet needs of patients with serious or life-threatening conditions.

“We view the fast track designation for our lead candidate, Nexvax2, as a testament to the significant need for bringing therapeutic solutions to patients with celiac disease as quickly as possible,” says Leslie Williams, Chief Executive officer for ImmusanT. 

“Currently, there are no disease-modifying therapies for this condition, and the only solution for patients is strict adherence to a lifelong, gluten-free diet. Our hope is that by helping restore immune tolerance towards gluten, Nexvax2 will improve quality of life and prevent the serious complications of chronic gluten exposure in celiac disease patients. The development of Nexvax2 aligns with our strategic vision of transforming how patients with autoimmune diseases are treated,” she explains.

Nexvax2 successfully moved into a Phase 2 clinical trial late last year following prior Phase 1 studies that proved it was safe and well tolerated at high dose levels.

Thousands of Australians had been awaiting the announcement, Michael Bell, President of Coeliac Australia, said at the roll-out of Phase 2.

ImmusanT is also working to advance therapeutically and diagnostically for other types of autoimmune disease, including Type 1 diabetes, lupus, multiple sclerosis and rheumatoid arthritis.

“With the learnings from Nexvax2, we are translating and applying this knowledge to additional autoimmune conditions,” Williams tells NutritionInsight.

What is celiac disease?
“Celiac disease is a life-changing condition that causes significant health problems due to cumulative damage from chronic and repetitive bouts of gluten-triggered inflammation. In earlier Phase 1 studies assessing Nexvax2, a relationship between dosing schedule, pharmacokinetics and systemic biomarkers as a pharmacodynamic readout in ESIT was demonstrated for the first time,” says Ken Truitt, M.D., Chief Medical Officer for ImmusanT.

Awareness around celiac disease is growing and it is estimated that the disease currently affects 2 to 3 million Americans and an estimated 1 percent of the global population.

It is a T-cell-mediated, chronic inflammatory disease of the intestine caused by an autoimmune-like reaction to dietary gluten proteins in genetically susceptible individuals.

When a person with celiac disease consumes gluten proteins in wheat, rye and barley, their immune system responds inappropriately by triggering T-cells specific for select epitopes (peptides) to fight the offending proteins (antigens), causing immune activation and acute digestive symptoms.

Ultimately, this reaction to ongoing gluten exposure causes chronic inflammation of the small intestine and compromises the body’s ability to absorb nutrients.

With rapidly increasing numbers of patients being diagnosed with the disease, there is a growing need for improved treatments. The only intervention currently available is a strict, lifelong gluten-free diet (GFD).

However, following a gluten-free diet can be complex and not always effective. Even the most diligent patients can suffer the adverse effects of accidental exposure.

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Packaging & Technology News

First time for Europe: Spanish supermarket chain launches Nutri-score labeling

16 Jan 2019 --- Spanish supermarket chain Eroski has introduced a handful of own-brand products featuring Nutri-Score labeling. This makes Eroski the first distribution company in Spain to incorporate this “advanced nutrition” labeling. The Nutri-Score system classifies foods into five levels, indicated by colored letters – from “A” in dark green to “E” in dark orange. It is calculated on the basis of the calories, the nutrients which are beneficial for our health – fiber, protein, amount of fruit, vegetables, nuts and pulses – and nutrients whose intake should be reduced – saturated fat, salt and sugar – per 100 grams of the product.

Health & Nutrition News

Has the haze lifted? As cannabis-derivatives get the green light, NPD expansion is set to grow

15 Jan 2019 --- Cannabis-derivatives, such as hemp and cannabidiol (CBD), have been increasingly cropping up on ingredients lists in the US and elsewhere. A recent ruling, which came as the US Government launched its farm bill in December 2018, alleviates hemp of its illegal status, which is expected to spur further innovation. Part one of this NutritionInsight two-part report into cannabis-derived products in the nutrition and food industry explored the softening regulatory environment. Part two considers how the industry may respond to the opportunities that such regulation shifts may bring to the US and Canada, for example.

Health & Nutrition News

A fresh look at fiber: Nutrient holds “surprisingly” significant disease prevention role

14 Jan 2019 --- Higher intake levels of dietary fiber and whole grains are being linked with a lower risk of non-communicable diseases, body weight and cholesterol levels, according to an extensive analysis published in The Lancet. The research highlights the importance of carbohydrate quality in our diets, which may be particularly salient as low carb diets continue to trend. “We understood fiber to be good for us, but we didn't realize just how good it is,” study author, Andrew Reynolds of the University of Otago, New Zealand, tells NutritionInsight.

Health & Nutrition News

Synbiotics in the mainstream? Danone boosts Activia Probiotic Dailies line with prebiotic fibers

10 Jan 2019 --- Food and beverage company Danone is adding two new flavors to it’s popular Dannon Activia Probiotic Dailies line, launched last year in the US; this time fortified with prebiotic fibers. Served up in a convenient “daily shot” format, the yogurt-based dose promises to deliver billions of live and active probiotics, and on-trend flavors: Lemon & Ginger and Honey & Ginger. The addition of prebiotic fibers to the line is a firm nod towards fiber, as although the ingredient on everyone's lips in 2018 may have been protein, fiber has been pegged to be huge in 2019.

Health & Nutrition News

On an all time high? Cannabis, hemp and CBD green lights fuel NPD surge

08 Jan 2019 --- As a string of regulatory greenlights have begun to move the cannabis plant and cannabis-derived products into an increasingly mainstream track, cannabis-derived products may well be the trend to watch in 2019. The FDA has signaled a softened stance on cannabis-derived products with its most recent move which has legalized hemp and Cannabidiol (CBD) derived from hemp. Such developments are exciting for the innovation front of food and drink products that contain cannabis-derived compounds. The future, it could be said, may be green.

More Articles
URL : http://www.nutritioninsight.com:80/news/worlds-first-celiac-vaccine-gains-fda-fast-track-designation-during-phase-2-trial.html